Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.43 |
| ▸ | CALCR | P30988 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11092435 | 0.90 | REN (0.47) | REN | |
| SCHEMBL31108671 | 0.89 | REN (0.55) | REN | |
| SCHEMBL31435690 | 0.87 | REN (0.58) | RENAPLNRRAMP3CALCR | |
| SCHEMBL29591887 | 0.85 | REN (0.47) | CAPN1CTSBREN | |
| SCHEMBL29592537 | 0.85 | SLC6A2 (0.47) | REN | |
| SCHEMBL30997440 | 0.84 | REN (0.45) | CAPN1CTSBREN | |
| SCHEMBL30997442 | 0.84 | REN (0.45) | CAPN1CTSBREN | |
| SCHEMBL30454361 | 0.84 | REN (0.51) | RENAPLNRF2 | |
| SCHEMBL31404231 | 0.84 | CAPN1 (0.59) | CAPN1CTSB | |
| SCHEMBL29590728 | 0.84 | CAPN1 (0.48) | CAPN1CTSBRENAPLNRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12453762-B2 | Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of glioblastoma | AMAL THERAPEUTICS SA (CH) | 2025-10-28 | — | — | US | disclosed |
| US-20250312428-A1 | Heterologous Prime Boost Vaccine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-10-09 | — | — | US | disclosed |
| US-12220450-B2 | Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for treatment of colorectal cancer | AMAL THERAPEUTICS SA (CH) | 2025-02-11 | — | — | US | disclosed |
| US-12220387-B2 | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer | AMAL THERAPEUTICS SA (CH) | 2025-02-11 | — | — | US | disclosed |
| US-12214048-B2 | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine | AMAL THERAPEUTICS SA (CH) | 2025-02-04 | — | — | US | disclosed |
| US-12178788-B2 | Complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist | AMAL THERAPEUTICS SA (CH) | 2024-12-31 | — | — | US | disclosed |
| EP-3515476-B1 | FUSION COMPRISING A CELL PENETRATING PEPTIDE, A MULTIEPITOPE AND A TLR PEPTIDE AGONIST FOR TREATMENT OF CANCER | AMAL THERAPEUTICS SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| EP-3429618-B1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3693009-B1 | A NOVEL COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR TREATMENT OF COLORECTAL CANCER | AMAL THERAPEUTICS SA (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240033336-A1 | TUMOR ANTIGENS, COMPOUNDS COMPRISING THE TUMOR ANTIGENS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-02-01 | — | — | US | disclosed |
| EP-4228681-A1 | COMBINATION OF A STING AGONIST AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST | Boehringer Ingelheim International GmbH (DE) | 2023-08-23 | — | — | EP | disclosed |
| EP-4210734-A1 | HETEROLOGOUS PRIME BOOST VACCINE | Boehringer Ingelheim International GmbH (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20220175933-A1 | Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Glioblastoma | AMAL THERAPEUTICS SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11338027-B2 | Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer | AMAL THERAPEUTICS SA (CH) | 2022-05-24 | — | — | US | disclosed |
| WO-2022079175-A1 | COMBINATION OF A STING AGONIST AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-21 | — | — | WO | disclosed |
| US-20220118102-A1 | COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE | AMAL THERAPEUTICS SA (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20220111028-A1 | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| US-20220088162-A1 | Heterologous Prime Boost Vaccine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| WO-2022053703-A1 | HETEROLOGOUS PRIME BOOST VACCINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220111028-A1 | Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist | STING1, TLR9, TLR3 | CAPN1 1593/4885CTSB 1394/4885REN 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.